Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
18.75
+0.53 (2.91%)
At close: Jul 11, 2025, 4:00 PM
19.10
+0.35 (1.87%)
After-hours: Jul 11, 2025, 7:07 PM EDT
Assembly Biosciences Revenue
Assembly Biosciences had revenue of $9.42M in the quarter ending March 31, 2025, with 62.82% growth. This brings the company's revenue in the last twelve months to $32.15M, up 148.33% year-over-year. In the year 2024, Assembly Biosciences had annual revenue of $28.52M with 298.16% growth.
Revenue (ttm)
$32.15M
Revenue Growth
+148.33%
P/S Ratio
3.80
Revenue / Employee
$440,466
Employees
73
Market Cap
143.20M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.52M | 21.36M | 298.16% |
Dec 31, 2023 | 7.16M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 6.25M | -72.85M | -92.09% |
Dec 31, 2020 | 79.11M | 63.14M | 395.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ASMB News
- 12 days ago - Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 - GlobeNewsWire
- 17 days ago - Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B - GlobeNewsWire
- 6 weeks ago - Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 2 months ago - New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 - GlobeNewsWire
- 3 months ago - Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress - GlobeNewsWire
- 4 months ago - Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights - GlobeNewsWire
- 4 months ago - Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - GlobeNewsWire